222 related articles for article (PubMed ID: 27418206)
1. Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).
Ostrom QT; Gittleman H; Kruchko C; Louis DN; Brat DJ; Gilbert MR; Petkov VI; Barnholtz-Sloan JS
J Neurooncol; 2016 Oct; 130(1):31-42. PubMed ID: 27418206
[TBL] [Abstract][Full Text] [Related]
2. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G
Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
[TBL] [Abstract][Full Text] [Related]
3. MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma.
Lei L; Jiang Z; Zhang G; Cheng Q; Lu H
World J Surg Oncol; 2018 Jun; 16(1):110. PubMed ID: 29914531
[TBL] [Abstract][Full Text] [Related]
4. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
5. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 1p/19q status combined with expression of p53 protein improves the diagnostic and prognostic evaluation of oligodendrogliomas.
Xiong J; Liu Y; Wang Y; Ke RH; Mao Y; Ye ZR
Chin Med J (Engl); 2010 Dec; 123(24):3566-73. PubMed ID: 22166632
[TBL] [Abstract][Full Text] [Related]
7. Case-Completeness of Nonmalignant Central Nervous System Tumors in the Canadian Cancer Registry, 2011-2015.
Zakaria D; Shaw A; Woods R; De P; Davis F
J Registry Manag; 2018; 45(1):117-131. PubMed ID: 31017881
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas.
Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T
Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285
[TBL] [Abstract][Full Text] [Related]
9. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Chamberlain MC
Neurology; 2014 Jun; 82(23):2147-8. PubMed ID: 24912510
[No Abstract] [Full Text] [Related]
10. Predictive biomarkers in adult gliomas: the present and the future.
Thomas L; Di Stefano AL; Ducray F
Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583
[TBL] [Abstract][Full Text] [Related]
11. Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors.
Kuo LT; Kuo KT; Lee MJ; Wei CC; Scaravilli F; Tsai JC; Tseng HM; Kuo MF; Tu YK
Int J Cancer; 2009 Jun; 124(12):2872-9. PubMed ID: 19330828
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological diagnosis of gliomas by genotype analysis].
Nakamura M; Shimada K; Nakase H; Konishi N
Brain Nerve; 2009 Jul; 61(7):773-80. PubMed ID: 19618854
[TBL] [Abstract][Full Text] [Related]
13. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
Juratli TA; Lautenschläger T; Geiger KD; Pinzer T; Krause M; Schackert G; Krex D
J Neurooncol; 2015 Sep; 124(2):197-205. PubMed ID: 26033545
[TBL] [Abstract][Full Text] [Related]
14. Lack of complete 1p19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis?
Gozé C; Rigau V; Gibert L; Maudelonde T; Duffau H
J Neurooncol; 2009 Jan; 91(1):1-5. PubMed ID: 18726074
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Schiff D
Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
[TBL] [Abstract][Full Text] [Related]
16. Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.
Hayashi S; Kitamura Y; Hirose Y; Yoshida K; Sasaki H
J Neurooncol; 2017 Mar; 132(1):119-126. PubMed ID: 28025770
[TBL] [Abstract][Full Text] [Related]
17. Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011.
Lym RL; Ostrom QT; Kruchko C; Couce M; Brat DJ; Louis DN; Barnholtz-Sloan JS
J Neurooncol; 2015 May; 123(1):43-51. PubMed ID: 25864099
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
[TBL] [Abstract][Full Text] [Related]
19. (11)C-methinine uptake correlates with MGMT promoter methylation in nonenhancing gliomas.
Okita Y; Nonaka M; Shofuda T; Kanematsu D; Yoshioka E; Kodama Y; Mano M; Nakajima S; Kanemura Y
Clin Neurol Neurosurg; 2014 Oct; 125():212-6. PubMed ID: 25178915
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Felsberg J; Rapp M; Loeser S; Fimmers R; Stummer W; Goeppert M; Steiger HJ; Friedensdorf B; Reifenberger G; Sabel MC
Clin Cancer Res; 2009 Nov; 15(21):6683-93. PubMed ID: 19861461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]